about
Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerThe impact of hypoxia and its modification of the outcome of radiotherapyImaging tumor hypoxia to advance radiation oncologyDefining normoxia, physoxia and hypoxia in tumours-implications for treatment responsePositron emission tomography to assess hypoxia and perfusion in lung cancerSustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia.Whole brain radiotherapy with radiosensitizer for brain metastasesAssessment of Blood Hemodynamics by USPIO-Induced R(1) Changes in MRI of Murine Colon Carcinoma.Detection of RTP801, a gene that is differentially expressed in irradiated HeLa cellsEffect of a topical vasodilator on tumor hypoxia and tumor oxygen guided radiotherapy using EPR oximetryRegulation of DNA repair mechanism in human glioma xenograft cells both in vitro and in vivo in nude mice.Effect of hyperoxia and hypercapnia on tissue oxygen and perfusion response in the normal liver and kidney.The influence of tumor oxygenation on (18)F-FDG (fluorine-18 deoxyglucose) uptake: a mouse study using positron emission tomography (PET)Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanomaHypoxia and radiation therapy: past history, ongoing research, and future promise.Six degrees of separation: the oxygen effect in the development of radiosensitizers.Dynamic oxygenation measurements using a phosphorescent coating within a mammary window chamber mouse model.Nicotinamide-rich diet improves physical endurance by up-regulating SUR2A in the heartInhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.Modulation of the tumor vasculature and oxygenation to improve therapyTargeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy.Hypoxia in head and neck cancer.Therapeutic applications of PARP inhibitors: anticancer therapy and beyondImmunohistochemical detection of changes in tumor hypoxiaTissue pO2 of orthotopic 9L and C6 gliomas and tumor-specific response to radiotherapy and hyperoxygenation.Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?Temporal variation in the response of tumors to hyperoxia with breathing carbogen and oxygen.Molecular aspects of tumour hypoxia.Synergistic combination of hyperoxygenation and radiotherapy by repeated assessments of tumor pO2 with EPR oximetry.PET-CT for radiotherapy treatment planning and response monitoring in solid tumors.Individualization of cancer treatment from radiotherapy perspective.Molecular imaging for personalized cancer care.Carbogen gas and radiotherapy outcomes in prostate cancer.Head and neck cancer: from anatomy to biology.Kinetic modeling in PET imaging of hypoxia.Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review.Chemoradiotherapy for squamous cell anal carcinoma: a review of prognostic factors.Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia.Noninvasive tumor hypoxia measurement using magnetic resonance imaging in murine U87 glioma xenografts and in patients with glioblastoma.Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers.
P2860
Q26766638-642FBE2E-8B0B-4ACB-A1B4-FFF898C5A1C9Q26779537-D850226C-CB99-4443-91BC-FE54FD0FA3ADQ27007862-655EA1DF-A952-4E61-AD77-9F0DE6DF865FQ27009437-D8E8402F-6645-4D5A-BF37-AA7728B9D860Q27026940-7B82F16C-7198-40CC-B0B1-DB1DCC9C6084Q27334035-65D06BC5-94AC-4596-B972-05AEC88F73B2Q33397865-C7E04256-3D06-46FE-9642-77102D64A91FQ33587272-EC20BAEC-8C10-494E-9C1E-1B149660FD81Q33746851-56C0C949-A610-45CB-B8E8-93A26F89E08DQ33882791-A01001F5-FC46-420A-A7AD-4B1D1759165AQ34056137-25B5326C-9A7B-4FA2-A416-72CE82616F5FQ34336394-19E0FC94-7BDA-4FE9-8016-71B19D6CF240Q34538538-D22DB6CA-EB52-425D-8F41-2170C4E1E0A6Q34603154-A602936E-37F5-4C83-B4E4-B5684C320453Q34986265-6873D50E-EAF7-49F3-99DB-1E422399432AQ35116798-E79A76F9-0F80-433A-B3FF-6F3A765000BFQ35162094-462B0017-FE3C-42EC-B3A1-42DEBAD47C27Q35216147-0661A526-9A9E-4E8A-B51E-0E9AEFC80511Q35329755-71297840-FDE3-490B-B2FC-F33DC9EB7A53Q35920685-9BFEFBA6-0FC8-47F6-BF22-5E76B1660AC9Q35975832-B886AEDF-6D3E-453B-8C21-08D292D4622FQ36541242-E9190168-33A4-4C34-8B87-46FEDB847565Q36853236-5AB073AF-3145-437F-8AC3-ACBF4D67D5B9Q37188441-1162340C-B5FA-4ECD-BDEE-C1F458060CF7Q37243472-02C254C5-55DA-4B9A-A1FE-5BCE05AE538FQ37373632-07EE5195-E7FD-4685-A938-50AD43DF1B97Q37415346-A938C864-A7DC-4C77-97BC-3E2E10FE298EQ37453827-7CB984B5-9495-4C63-9BCD-5C1BD5CBD2EBQ37639982-757AF645-0E0E-4C0D-9EA8-72384D980662Q37832131-367CDA4C-6460-4940-966F-49E864246633Q37989616-44B94842-14F7-4D7A-B1B8-E63AB21410A2Q37999206-4DD5DE55-5E41-4312-9869-3FC5D3A9F8A7Q38078362-D34F37B4-496F-4520-AC67-F72BE8E01C99Q38082457-6F03EAAD-BF4D-4E94-8469-7CB026050800Q38253648-96BC3226-46A6-4ADD-B98A-FF7D4261C14DQ38445971-AE41CDA7-8CC3-48DA-AEFC-0BA52C787926Q38793604-049217E3-17E4-405B-A041-60E2250AA61FQ39015424-2C402EAD-6E0E-483F-BA31-FE9F5751B18DQ39135499-9AF2924B-4407-499E-84BC-65743A50C414Q39668588-15736AE6-69EB-4EAD-99B3-F156C343E101
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
ARCON: a novel biology-based approach in radiotherapy.
@ast
ARCON: a novel biology-based approach in radiotherapy.
@en
type
label
ARCON: a novel biology-based approach in radiotherapy.
@ast
ARCON: a novel biology-based approach in radiotherapy.
@en
prefLabel
ARCON: a novel biology-based approach in radiotherapy.
@ast
ARCON: a novel biology-based approach in radiotherapy.
@en
P1433
P1476
ARCON: a novel biology-based approach in radiotherapy.
@en
P2093
Albert J van der Kogel
Johannes H A M Kaanders
P304
P356
10.1016/S1470-2045(02)00929-4
P577
2002-12-01T00:00:00Z